Test ID: CHIKV Chikungunya IgM and IgG, Antibody, Serum
Useful For
Aiding in the diagnosis of recent infection with Chikungunya virus in patients with recent travel to endemic areas and a compatible clinical syndrome
Profile Information
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
CHIKM | Chikungunya IgM, Ab, S | No | Yes |
CHIKG | Chikungunya IgG, Ab, S | No | Yes |
CHIKI | Chikungunya Interpretation | No | Yes |
Method Name
CHIKM, CHIKG: Enzyme-Linked Immunosorbent Assay (ELISA)
CHIKI: Technical Interpretation
Reporting Name
Chikungunya IgM and IgG, Ab, SSpecimen Type
SerumOrdering Guidance
Testing a patient in a convalescent period is recommended because specimens collected too early following infection may be negative for antibodies to Chikungunya virus.
Specimen Required
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 0.5 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Specimen Minimum Volume
0.4 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 30 days | |
Frozen | 30 days |
Clinical Information
Chikungunya virus (ChikV) is a single-stranded RNA alphavirus and a member of the Togaviridae family of viruses. The name Chikungunya is derived from the language of the Makonde ethnic groups in southeast Africa and means "that which bends" or "stooped walk." This is in reference to the hunched-over appearance of infected individuals due to the characteristically painful and incapacitating arthralgia caused by the virus. ChikV is endemic throughout Africa, India, and, more recently, the Caribbean islands. In 2014, the first case of autochthonous, or local transmission, in the United States occurred in Florida.
Humans are the primary reservoir for ChikV and Aedes species mosquitos are the primary vectors for transmission. Unlike other mosquito-borne viruses, such as West Nile virus and Dengue, the majority of individuals who are exposed to ChikV become symptomatic, with the most severe manifestations observed at the extremes of age and in those with suppressed immunity. Once exposed to ChikV, individuals develop lasting immunity and protection from reinfection.
Prior to development of symptoms, the incubation period ranges, on average, from 3 to 7 days. Infected patients typically present with sudden-onset high fever, incapacitating joint pain, and often a maculopapular rash lasting anywhere from 3 to 10 days. Notably, symptom relapse can occur in some individuals 2 to 3 months following resolution of initial symptoms. Currently, there are no licensed vaccines and treatment is strictly supportive care.
Reference Values
IgM: Negative
IgG: Negative
Reference values apply to all ages.
Interpretation
IgM and IgG Negative:
-No serologic evidence of exposure to Chikungunya virus. Repeat testing on a new specimen collected in 5 to 10 days is recommended if clinical suspicion persists.
IgM and IgG Positive:
-IgM and IgG antibodies to Chikungunya virus detected, suggesting recent or past infection. IgM antibodies to Chikungunya virus may remain detectable for 3 to 4 months post-infection.
IgM Positive, IgG Negative:
-IgM antibodies to Chikungunya virus detected, suggesting recent infection. Repeat testing in 5 to 10 days is recommended to demonstrate anti-Chikungunya virus IgG seroconversion to confirm current infection.
IgM Negative, IgG Positive:
-IgG antibodies to Chikungunya virus detected, suggesting past infection.
IgM and/or IgG Borderline:
-Repeat testing in 10 to 14 days is recommended.
Clinical Reference
Lwande OW, Obanda V, Bucht G, et al. Global emergence of Alphaviruses that cause arthritis in humans. Infect Ecol Epidemiol. 2015;5:29853. doi:10.3402/iee.v5.29853
Day(s) Performed
Bimonthly on the second and fourth Wednesday; fifth Wednesday when applicable
Report Available
Same day/1 to 14 daysTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
86790 x2
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
CHIKV | Chikungunya IgM and IgG, Ab, S | 93976-9 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
CHIKI | Chikungunya Interpretation | 69048-7 |
CHIKG | Chikungunya IgG, Ab, S | 88630-9 |
CHIKM | Chikungunya IgM, Ab, S | 88629-1 |
Forms
If not ordering electronically, complete, print, and send Infectious Disease Serology Test Request (T916) with the specimen.
Testing Algorithm
For more information see Mosquito-borne Disease Laboratory Testing.
Special Instructions
mml-mosquitoborne